title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
103 Biggest Movers From Yesterday,20220511T102237,https://www.benzinga.com/news/22/05/27130447/103-biggest-movers-from-yesterday,SGEN,0.06399,Neutral,0.011826
"Earnings Scheduled For April 28, 2022",20220428T085040,https://www.benzinga.com/news/earnings/22/04/26860440/earnings-scheduled-for-april-28-2022,SGEN,0.014477,Neutral,-0.108204
Pyxis Oncology M&A Spotlight Signals Potential Growth Amidst Competitive ADC Landscape: Analyst - Pyxis Oncology  ( NASDAQ:PYXS ) ,20230905T164314,https://www.benzinga.com/general/biotech/23/09/34244004/pyxis-oncology-m-a-spotlight-signals-potential-growth-amidst-competitive-adc-landscape-analyst,SGEN,0.277433,Neutral,0.087105
Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors - Impel Pharmaceuticals  ( NASDAQ:IMPL ) ,20230412T200100,https://www.benzinga.com/pressreleases/23/04/g31776707/impel-pharmaceuticals-announces-appointment-of-darren-cline-to-the-board-of-directors,SGEN,0.054794,Neutral,0.008984
Marinus  ( MRNS )  to Sell Rare Disease PRV to Novo Nordisk,20220715T154300,https://www.zacks.com/stock/news/1953027/marinus-mrns-to-sell-rare-disease-prv-to-novo-nordisk,SGEN,0.254307,Neutral,0.083778
Vaxcyte  ( PCVX )  Completes Enrollment in Pneumococcal Disease Study,20220714T155900,https://www.zacks.com/stock/news/1952493/vaxcyte-pcvx-completes-enrollment-in-pneumococcal-disease-study,SGEN,0.246582,Neutral,0.073851
Rhythm  ( RYTM )  Surges on Upbeat Data on Lead Product Candidate,20220713T161500,https://www.zacks.com/stock/news/1951929/rhythm-rytm-surges-on-upbeat-data-on-lead-product-candidate,SGEN,0.247208,Neutral,0.096362
Pliant Therapeutics  ( PLRX )  Up on Positive Data From Lung Disease Study,20220712T150100,https://www.zacks.com/stock/news/1951160/pliant-therapeutics-plrx-up-on-positive-data-from-lung-disease-study,SGEN,0.282234,Somewhat-Bullish,0.152928
"Pancreatic Endocrine Tumor Market is Expected to Expand at a Healthy Growth Rate by 2032, Assesses DelveInsight | Key Companies - Merck, Theradex, SynerGene, Mirati, Novartis, Syntrix Biosystems, Eli Lilly, Boehringer Ingelheim",20230803T210100,https://www.prnewswire.com/news-releases/pancreatic-endocrine-tumor-market-is-expected-to-expand-at-a-healthy-growth-rate-by-2032-assesses-delveinsight--key-companies---merck-theradex-synergene-mirati-novartis-syntrix-biosystems-eli-lilly-boehringer-ingelheim-301892397.html,SGEN,0.041466,Neutral,-0.017808
"Why IMARA Shares Are Trading Higher By Over 13%; Here Are 22 Stocks Moving Premarket - Black Diamond Therapeutic  ( NASDAQ:BDTX ) , Avenue Therapeutics  ( NASDAQ:ATXI ) ",20221014T113437,https://www.benzinga.com/news/22/10/29266749/why-imara-shares-are-trading-higher-by-over-13-here-are-22-stocks-moving-premarket,SGEN,0.072217,Neutral,0.064821
"Breast Cancer Monoclonal Antibodies Market to grow by USD 15 billion from 2022 to 2027, North America to account ... - PR Newswire",20230918T091500,https://www.prnewswire.com/news-releases/breast-cancer-monoclonal-antibodies-market-to-grow-by-usd-15-billion-from-2022-to-2027-north-america-to-account-for-42-of-market-growth---technavio-301929309.html,SGEN,0.043108,Neutral,0.0
"Cutaneous Melanoma Market is Predicted to Exhibit Remarkable Growth, Predicts DelveInsight | Key Companies - Merck, Amgen, Anaveon, Eisai, Regeneron, BMS, AstraZeneca, Seagen, Novartis, Eli Lilly and Company",20230724T210100,https://www.prnewswire.com/news-releases/cutaneous-melanoma-market-is-predicted-to-exhibit-remarkable-growth-predicts-delveinsight--key-companies---merck-amgen-anaveon-eisai-regeneron-bms-astrazeneca-seagen-novartis-eli-lilly-and-company-301883725.html,SGEN,0.05381,Neutral,0.031999
Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,20230703T210100,https://www.prnewswire.com/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868673.html,SGEN,0.020404,Neutral,-0.004464
Antibody-drug Conjugates Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain,20230626T210100,https://www.prnewswire.com/news-releases/antibody-drug-conjugates-clinical-trial-pipeline-experiences-momentum-delveinsight-estimates-a-diverse-pipeline-comprising-180-companies-working-in-the-domain-301862784.html,SGEN,0.104228,Neutral,0.00218
"Illumina, Seagen And Other Big Stocks Moving Higher On Monday - Agenus  ( NASDAQ:AGEN ) , First Majestic Silver  ( NYSE:AG ) ",20230313T145550,https://www.benzinga.com/news/23/03/31322709/illumina-seagen-and-other-big-stocks-moving-higher-on-monday,SGEN,0.162802,Neutral,0.13894
"Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know - iShares Biotechnology ETF  ( NASDAQ:IBB ) , BondBloxx ETF Trust BondBloxx BB-Rated USD High Yield Corporate Bond ETF  ( ARCA:XBB ) ",20221101T200154,https://www.benzinga.com/general/biotech/22/11/29508633/provention-bios-second-try-apelliss-eye-disorder-drug-review-3-adcom-verdicts-and-more-novembers-,SGEN,0.09402,Neutral,0.0
"Regional banks pace decliners, as biotech deals lift Seagen and Provention Bio",20230313T143200,https://www.marketwatch.com/story/regional-banks-pace-decliners-as-biotech-deals-lift-seagen-and-provention-bio-78a5d161,SGEN,0.485711,Somewhat-Bullish,0.178968
77 Stocks Moving In Tuesday's Mid-Day Session,20220510T160029,https://www.benzinga.com/news/22/05/27114947/77-stocks-moving-in-tuesdays-mid-day-session,SGEN,0.089052,Neutral,0.005701
"Head and Neck Squamous Cell Carcinoma Market to Witness Upsurge in Growth by 2032, Assesses DelveInsight | Key Companies in the Market - Pfizer, Merck, Eisai, AstraZeneca, Innate, Roche, GlaxoSmithKline, BeiGene, IO Biotech, Incyte",20230918T210100,https://www.prnewswire.com/news-releases/head-and-neck-squamous-cell-carcinoma-market-to-witness-upsurge-in-growth-by-2032-assesses-delveinsight--key-companies-in-the-market---pfizer-merck-eisai-astrazeneca-innate-roche-glaxosmithkline-beigene-io-biotech-incyt-301930322.html,SGEN,0.023146,Neutral,0.04357
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated - Biogen  ( NASDAQ:BIIB ) ,20230728T155617,https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33444357/reatas-acquisition-fits-biogens-strategy-despite-high-cost-analyst-says-high-level-,SGEN,0.280615,Neutral,0.0
Medical Second Opinion Global Market to Register Stunning Growth at a CAGR of ~17% by 2028 | DelveInsight,20230821T210100,https://www.prnewswire.com/news-releases/medical-second-opinion-global-market-to-register-stunning-growth-at-a-cagr-of-17-by-2028--delveinsight-301905294.html,SGEN,0.024347,Neutral,-0.03954
"The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill",20220707T140337,https://www.benzinga.com/general/biotech/22/07/27983728/the-daily-biotech-pulse-mercks-potential-seagen-buyout-expected-in-weeks-fda-holds-diamedicas-str,SGEN,0.130358,Neutral,0.001058
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference,20230906T111100,https://www.globenewswire.com/news-release/2023/09/06/2738237/0/en/LAVA-Therapeutics-to-Participate-in-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html,SGEN,0.155451,Neutral,0.015251
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results,20230822T110000,https://www.globenewswire.com/news-release/2023/08/22/2729337/0/en/LAVA-Therapeutics-Provides-Business-Update-and-Reports-Second-Quarter-2023-Financial-Results.html,SGEN,0.12546,Neutral,0.066
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference - LAVA Therapeutics  ( NASDAQ:LVTX ) ,20230814T110026,https://www.benzinga.com/pressreleases/23/08/g33825889/lava-therapeutics-to-participate-in-the-h-c-wainwright-immune-cell-engager-virtual-conference,SGEN,0.135347,Neutral,0.01396
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference,20230814T110000,https://www.globenewswire.com/news-release/2023/08/14/2724253/0/en/LAVA-Therapeutics-to-Participate-in-the-H-C-Wainwright-Immune-Cell-Engager-Virtual-Conference.html,SGEN,0.162802,Neutral,0.015762
"Lava  ( LVTX )  Discontinues Hematological Tumor Study, Shares Fall",20230615T134300,https://www.zacks.com/stock/news/2108856/lava-lvtx-discontinues-hematological-tumor-study-shares-fall,SGEN,0.235823,Somewhat-Bullish,0.220485
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway,20230614T130000,https://www.globenewswire.com/news-release/2023/06/14/2688107/0/en/LAVA-Therapeutics-Provides-Updates-on-Clinical-Programs-and-Extends-the-Cash-Runway.html,SGEN,0.035555,Neutral,0.010857
LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results,20230608T110000,https://www.globenewswire.com/news-release/2023/06/08/2684602/0/en/LAVA-Therapeutics-Provides-Business-Update-and-Reports-First-Quarter-2023-Financial-Results.html,SGEN,0.083347,Neutral,0.034123
LAVA  ( LVTX )  Up on J&J's  ( JNJ )  Cancer Study Candidate Selection,20230602T145900,https://www.zacks.com/stock/news/2103223/lava-lvtx-up-on-jjs-jnj-cancer-study-candidate-selection,SGEN,0.301933,Neutral,0.102336
LAVA Announces Annual Meeting of Shareholders,20230530T212800,https://www.globenewswire.com/news-release/2023/05/30/2678898/0/en/LAVA-Announces-Annual-Meeting-of-Shareholders.html,SGEN,0.131643,Neutral,-0.023497
Seagen Inc.  ( SGEN )  Q3 2022 Earnings Call Transcript,20221028T063039,https://www.fool.com/earnings/call-transcripts/2022/10/28/seagen-inc-sgen-q3-2022-earnings-call-transcript/,SGEN,0.030978,Neutral,0.13554
Analyst Says This Small Cap Stock Might Be 'Game Changer' In Bispecific T Cell Engagers Space - LAVA Therapeutics  ( NASDAQ:LVTX ) ,20221025T182626,https://www.benzinga.com/analyst-ratings/analyst-color/22/10/29403318/analyst-says-this-small-cap-stock-might-be-game-changer-in-bispecific-t-cell-engage,SGEN,0.16849,Neutral,-0.143063
Will Seagen's  ( SGEN )  Portfolio of Drugs Help Combat Rivalry?,20221004T140500,https://www.zacks.com/stock/news/1987853/will-seagens-sgen-portfolio-of-drugs-help-combat-rivalry,SGEN,0.48724,Somewhat-Bullish,0.239425
Seagen  ( SGEN )  Inks Deal With LAVA Therapeutics for LAVA-1223,20220927T154400,https://www.zacks.com/stock/news/1985550/seagen-sgen-inks-deal-with-lava-therapeutics-for-lava-1223,SGEN,0.423843,Somewhat-Bullish,0.283577
"Nasdaq Turns Lower; Crude Oil Drops Sharply - Golden Sun Education Gr  ( NASDAQ:GSUN ) , Aditxt  ( NASDAQ:ADTX ) ",20220926T184935,https://www.benzinga.com/news/earnings/22/09/29018181/nasdaq-turns-lower-crude-oil-drops-sharply,SGEN,0.235823,Bullish,0.433772
Hot Penny Stocks To Watch As The Stock Market Crash Continues,20220926T183016,https://pennystocks.com/featured/2022/09/26/hot-penny-stocks-to-watch-as-the-stock-market-crash-continues/,SGEN,0.075995,Neutral,0.10047
"Stocks making the biggest moves midday: Wynn Resorts, Planet Fitness, AMC, Lyft and more",20220926T164736,https://www.cnbc.com/2022/09/26/stocks-making-the-biggest-moves-midday-wynn-resorts-planet-fitness-amc-lyft-and-more.html,SGEN,0.067536,Neutral,0.080183
"Dow Drops Over 100 Points; Crude Oil Rises Over 1% - Golden Sun Education Gr  ( NASDAQ:GSUN ) , Inpixon  ( NASDAQ:INPX ) ",20220926T161059,https://www.benzinga.com/news/earnings/22/09/29014630/dow-drops-over-100-points-crude-oil-rises-over-1,SGEN,0.227716,Bullish,0.423445
"US Stocks Mostly Higher; Nasdaq Rises Over 100 Points - Aditxt  ( NASDAQ:ADTX ) , Avenue Therapeutics  ( NASDAQ:ATXI ) ",20220926T142818,https://www.benzinga.com/news/22/09/29010889/us-stocks-mostly-higher-nasdaq-rises-over-100-points,SGEN,0.204072,Bullish,0.39278
Why LAVA Therapeutics Stock Is Up More Than 100% Today - LAVA Therapeutics  ( NASDAQ:LVTX ) ,20220926T132755,https://www.benzinga.com/news/22/09/29008452/why-lava-therapeutics-stock-is-up-more-than-100-today,SGEN,0.712594,Bullish,0.424266
LAVA Therapeutics Skyrockets After Cancer Agreement With Seagen - Seagen  ( NASDAQ:SGEN ) ,20220926T123856,https://www.benzinga.com/general/biotech/22/09/29007424/lava-therapeutics-skyrockets-after-cancer-agreement-with-seagen,SGEN,0.629492,Somewhat-Bullish,0.259257
"Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors",20220926T120000,https://www.globenewswire.com/news-release/2022/09/26/2522463/0/en/Seagen-and-LAVA-Therapeutics-Announce-Exclusive-Worldwide-License-Agreement-to-Advance-LAVA-1223-a-Preclinical-Gamma-Delta-Bispecific-T-Cell-Engager-for-EGFR-Expressing-Solid-Tumor.html,SGEN,0.427184,Neutral,0.1429
5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good,20230613T133000,https://www.zacks.com/commentary/2107444/5-biotech-stocks-to-buy-as-industry-prospects-for-2h23-look-good,SGEN,0.023191,Neutral,0.069874
"Zacks Industry Outlook Highlights CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals",20230322T113700,https://www.zacks.com/stock/news/2068930/zacks-industry-outlook-highlights-crispr-therapeutics-ligand-pharmaceuticals-theseus-pharmaceuticals-and-kala-pharmaceuticals,SGEN,0.026013,Neutral,0.017488
4 Biotech Stocks to Consider for Your Portfolio in 2023,20230321T153200,https://www.zacks.com/commentary/2068484/4-biotech-stocks-to-consider-for-your-portfolio-in-2023,SGEN,0.02689,Neutral,0.098044
